Clinical

Dataset Information

0

A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab


ABSTRACT: This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2195502 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2270464 | ecrin-mdr-crc
| 2312043 | ecrin-mdr-crc
| 2181974 | ecrin-mdr-crc
| 2113074 | ecrin-mdr-crc
| 2140914 | ecrin-mdr-crc
| 2535112 | ecrin-mdr-crc
| 2284699 | ecrin-mdr-crc
| 2096992 | ecrin-mdr-crc
| 2107060 | ecrin-mdr-crc
| S-EPMC5885260 | biostudies-literature